2020
DOI: 10.1056/nejmoa2024671
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Methods Nonhuman primates received 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before u… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

66
1,028
10
11

Year Published

2020
2020
2021
2021

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 976 publications
(1,115 citation statements)
references
References 42 publications
66
1,028
10
11
Order By: Relevance
“…Although non-human primates represent an attractive model for SARS-CoV-2 vaccine development [2][3][4][5] , multiple studies [26][27][28] including our own suggest that the Syrian hamster provides an effective animal model to evaluate SARS-CoV-2 vaccine e cacy for the following reasons: 1) low dose (i.e. 10 2 -10 3 TCID 50 ) i.n.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Although non-human primates represent an attractive model for SARS-CoV-2 vaccine development [2][3][4][5] , multiple studies [26][27][28] including our own suggest that the Syrian hamster provides an effective animal model to evaluate SARS-CoV-2 vaccine e cacy for the following reasons: 1) low dose (i.e. 10 2 -10 3 TCID 50 ) i.n.…”
Section: Discussionmentioning
confidence: 99%
“…The scienti c community, including critical industry and academic partnerships, have embarked on an unprecedented race to develop and produce effective COVID-19 vaccine(s) for global use 1 . Several recent reports validate the SARS-CoV-2 Spike (S) protein as a promising target for COVID-19 vaccine development [2][3][4][5] . However, these approaches utilise platforms based on nucleic acids, viral vectors or insect cell production systems which could face challenges during large-scale manufacture and distribution.…”
Section: Introductionmentioning
confidence: 94%
“…Multiple studies employing a variety of vaccine formulations and modalities have now demonstrated that SARS-CoV-2 viral neutralization titers in small animals including mice and guinea pigs are predictive of immunogenicity in macaques and humans ( Figure 5E) [17][18][19][20]22,23,[33][34][35][36][37][40][41][42][43]45 . Despite promising immunogenicity in several cases, all of the above liquid formulations were either refrigerated or frozen prior to use.…”
Section: Discussionmentioning
confidence: 99%
“…We also know from the HIV/simian immunodeficiency virus/simian human immunodeficiency virus (and no doubt other) vaccines that it's easier to protect 4 . And variation in the challenge stock/dose/route is generally true across the macaque challenge studies.…”
Section: Gamentioning
confidence: 99%